208TiP SOLTI-1303 PATRICIA: Cohort C. Combination of palbociclib with trastuzumab and endocrine therapy (ET) versus treatment of physician’s choice (TPC) in pretreated HER2-positive and hormone receptor-positive (HER2+/HR+) / PAM50 luminal metastatic breast cancer (BC): A randomized phase II trial
Ciruelos, E.M., Ponce, J., Pernas Simon, S., Cortés, J., Cantos, B., Garate, E., Vega Alonso, E., Mele Olive, M., Martinez De Dueñas, E., Montaño Perianez, A., Martinez, N., Perello Martorell, A., Bermejo De Las Heras, B., Arqueros Nunez, C., Fernández, I., De la Haba Rodriguez, J., Oliveira, M., González, X., Villagrasa Gonzalez, P., Prat, A.
Published in Annals of oncology (01.05.2022)
Published in Annals of oncology (01.05.2022)
Get full text
Journal Article